文献速递系统性红斑狼疮

Anifrolumab(抗干扰素α受体单抗)治疗中重度系统性红斑狼疮的IIb期研究

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Rheumatol · 2017-01-01

这项IIb期随机双盲安慰剂对照研究纳入305例中重度SLE患者,评估anifrolumab(300mg或1000mg)联合标准治疗的疗效与安全性。24周主要终点(SRI[4]应答且激素持续减量)在300mg组显著优于安慰剂,52周多个终点亦改善,带状疱疹和流感报告增多,严重不良事件发生率组间相似。

要点

  • 24周主要终点达标率:anifrolumab 300mg组34.3%、1000mg组28.8%,安慰剂组17.6%。
  • 基线I型IFN高表达患者中anifrolumab疗效更明显,300mg组36.0% vs 安慰剂13.2%。
  • 52周SRI(4)、BICLA、改良SRI(6)和主要临床缓解等终点anifrolumab组均优于安慰剂。

核心结论

  • Anifrolumab在中重度SLE患者中较安慰剂显著降低疾病活动度,多个临床终点均显示获益。

研究设计与样本

  • IIb期随机双盲安慰剂对照研究,纳入305例中重度SLE成人患者。
  • 患者随机接受静脉anifrolumab 300mg、1000mg或安慰剂,每4周一次,共48周,均联合标准治疗。
  • 随机分层因素包括SLEDAI-2000评分(<10或≥10)、口服激素剂量(<10或≥10mg/天)和基于4基因表达检测的I型IFN基因签名状态(高或低)。

主要发现

  • 24周主要终点(SRI[4]应答且口服激素持续减量至<10mg/天且≤第1周剂量)达标率:300mg组34.3%(99例中)、1000mg组28.8%(104例中)、安慰剂组17.6%(102例中),P值分别为0.014和0.063。
  • 基线I型IFN高表达患者中主要终点达标率:安慰剂组13.2%,anifrolumab 300mg组36.0%(P=0.004),1000mg组28.2%(P=0.029)。
  • 52周SRI(4)应答率:安慰剂组40.2%,300mg组62.6%(P<0.001),1000mg组53.8%(P=0.043)。
  • 52周BICLA应答率:安慰剂组25.7%,300mg组53.5%(P<0.001),1000mg组41.2%(P=0.018);改良SRI(6)应答率分别为28.4%、49.5%(P=0.002)、44.7%(P=0.015)。
  • 52周主要临床缓解率(第24至52周所有器官域BILAG 2004 C级或更好):安慰剂组6.9%,300mg组19.2%(P=0.012),1000mg组17.3%(P=0.025)。

关键数值与推荐

  • 主要终点为第24周SRI[4]应答且口服激素持续减量(<10mg/天且从第12周到24周≤第1周剂量)。
  • 其他终点包括第52周SRI(4)、BICLA、改良SRI(6)和主要临床缓解等。
  • 主要终点在改良意向治疗(ITT)人群和I型IFN高表达亚组中分析,任一人群达到主要终点即认为研究阳性。
  • 主要终点分析在2个人群中各自控制双侧α=0.10。

临床怎么用

  • Anifrolumab联合标准治疗可改善中重度SLE的多个临床应答指标,尤其对基线I型IFN高表达患者可能获益更明显。
  • 治疗期间需关注带状疱疹和流感报告增多,严重不良事件发生率与安慰剂组相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double-blind, placebo-controlled study of adults with moderate-to-severe systemic lupus erythematosus (SLE). METHODS: Patients (n = 305) were randomized to receive intravenous anifrolumab (300 mg or 1,000 mg) or placebo, in addition to standard therapy, every 4 weeks for 48 weeks. Randomization was stratified by SLE Disease Activity Index 2000 score (<10 or ≥10), oral corticosteroid dosage (<10 or ≥10 mg/day), and type I IFN gene signature test status (high or low) based on a 4-gene expression assay. The primary end point was the percentage of patients achieving an SLE Responder Index (SRI[4]) response at week 24 with sustained reduction of oral corticosteroids (<10 mg/day and less than or equal to the dose at week 1 from week 12 through 24). Other end points (including SRI[4], British Isles Lupus Assessment Group [BILAG]-based Composite Lupus Assessment [BICLA], modified SRI[6], and major clinical response) were assessed at week 52. The primary end point was analyzed in the modified intent-to-treat (ITT) population and type I IFN-high subpopulation. The study result was considered positive if the primary end point was met in either of the 2 study populations. The Type I error rate was controlled at 0.10 (2-sided), within each of the 2 study populations for the primary end point analysis. RESULTS: The primary end point was met by more patients treated with anifrolumab (34.3% of 99 for 300 mg and 28.8% of 104 for 1,000 mg) than placebo (17.6% of 102) (P = 0.014 for 300 mg and P = 0.063 for 1,000 mg, versus placebo), with greater effect size in patients with a high IFN signature at baseline (13.2% in placebo-treated patients versus 36.0% [P = 0.004] and 28.2% [P = 0.029]) in patients treated with anifrolumab 300 mg and 1,000 mg, respectively. At week 52, patients treated with anifrolumab achieved greater responses in SRI(4) (40.2% versus 62.6% [P < 0.001] and 53.8% [P = 0.043] with placebo, anifrolumab 300 mg, and anifrolumab 1,000 mg, respectively), BICLA (25.7% versus 53.5% [P < 0.001] and 41.2% [P = 0.018], respectively), modified SRI(6) (28.4% versus 49.5% [P = 0.002] and 44.7% [P = 0.015], respectively), major clinical response (BILAG 2004 C or better in all organ domains from week 24 through week 52) (6.9% versus 19.2% [P = 0.012] and 17.3% [P = 0.025], respectively), and several other global and organ-specific end points. Herpes zoster was more frequent in the anifrolumab-treated patients (2.0% with placebo treatment versus 5.1% and 9.5% with anifrolumab 300 mg and 1,000 mg, respectively), as were cases reported as influenza (2.0% versus 6.1% and 7.6%, respectively), in the anifrolumab treatment groups. Incidence of serious adverse events was similar between groups (18.8% versus 16.2% and 17.1%, respectively). CONCLUSION: Anifrolumab substantially reduced disease activity compared with placebo across multiple clinical end points in the patients with moderate-to-severe SLE.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017. PMID: 28130918. doi:10.1002/art.39962

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。